Cost-Consciousness Raising: Adding Value To Cancer Drug Development
This article was originally published in Pharmaceutical Approvals Monthly
As the market attempts to reconcile the high prices of revolutionary new cancer therapies with pressure to control rising health care costs, oncology associations call for new drugs to demonstrate clinical value in addition to meeting FDA’s standards of safety and efficacy. Can “continuous learning systems” help?
You may also be interested in...
“Financial toxicity” should be considered by oncologists in use of new, targeted therapies, oncology association says. A new list of practices to avoid puts drug costs more squarely in crosshairs than first version in 2012.
The American Society of Clinical Oncology takes the first big step toward a real-time learning network by aggregating data culled from electronic health records, to provide physicians, patients and others with up-to-the-minute evidence on how best to treat cancer.
Over the last two years, UnitedHealthcare and Aetna have launched cancer pathway programs with the overall goals of standardizing and improving care and lowering cost. Drug therapy is a key focus.